(E)-4-(4-Acrylamidophenoxy)-N-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model
Molecules · 20.05.2026 · 31 (10) · 1757
DOI: 10.3390/molecules31101757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 20.05.2026. Verfasst von Ganga Reddy Velma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Advanced Materials & Industrial Chemistry (CAMIC), School of Science, RMIT University, GPO BOX 2476, Melbourne, VIC 3001, Australia. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Angiogenesis Inhibitors, Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UGC, CSIR, New Delhi.
Abstract (Originalsprache)
Pharmacophore hybridization is a well-established strategy for developing novel anticancer agents with improved biological profiles. In this study, a new series of (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide derivatives has been rationally designed by hybridizing key structural features of sorafenib with cinnamide pharmacophores and subsequently synthesized. The antiproliferative activities of the synthesized compounds were evaluated against a panel of human cancer cell lines, including A549 (lung), DU-145 (prostate), SKOV3 (ovarian), and HepG2 (liver), along with non-cancerous Hek293T cells. In comparison with the standard drug sorafenib, most of the (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamides demonstrated significant antiproliferative activity, with specificity toward the HepG2 (liver cancer) cell line, and no effect on the noncancerous cells (Hek293T). Among them, compound 5f, the derivative containing a trifluoromethyl-substituted cinnamoyl moiety was identified as the lead candidate, exhibiting an IC50 of 5.3 µM towards HepG2 (liver) cancer cells, comparable to the reference drug sorafenib. Enzyme inhibition studies showed that compound 5f inhibited both b-Raf and VEGFR-2 with IC50 values of 1.45 and 0.37 µM, respectively. Furthermore, compound 5f suppressed angiogenesis in vitro and in vivo, as evidenced by the tube formation assay using HUVECs and in transgenic zebrafish Tg(fli1a:EGFP) models, respectively. Mechanistic studies indicated that compound 5f induced apoptosis in HepG2 cells through mitochondrial membrane depolarization and increased ROS generation. Molecular docking studies supported experimental findings and showed that 5f can interact with catalytically active residues via hydrogen-bonding interactions. Overall, these results highlight the potential of compound 5f as a promising dual target therapeutic lead with dual direct anticancer and antiangiogenic properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Advanced Materials & Industrial Chemistry (CAMIC), School of Science, RMIT University, GPO BOX 2476, Melbourne, VIC 3001, Australia.
- Academy of Scientific and Innovative Research (AcSIR), Anusandhan Bhawan, 2-Rafi Marg, New Delhi 110 001, India.
- Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500 007, India.
- Accelerator for Translational Research in Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, STEM College, RMIT University, Melbourne, VIC 3083, Australia.
- Department of Biochemistry, Chemical Synthesis Core Facility, Albert Einstein College of Medicine, Gruss MRRC-314, Bronx, NY 10461, USA.
- Department of Pharmaceutical Sciences, Guru Gobind Singh College of Pharmacy, Yamuna Nagar 135 001, India.
ORCID-Profile: Ganga Reddy Velma, Srinivasa Reddy Telukutla, Jayaram Vankudoth, Ajmer Singh Grewal, Ravikumar Akunuri, Donald Wlodkowic, Srihari Pabbaraja, Suresh K Bhargava, Magdalena Plebanski, Ahmed Kamal
Förderung
- UGC
- CSIR
- New Delhi
- ACT
- RMIT Micro Nano Research Facility
- ANFF Victorian Node, Australia
- ANRF PM Professorship Program
- Osmania University, Hyderabad
Zitieren
APA
Velma, G. R., Telukutla, S. R., Vankudoth, J., Grewal, A. S., Privér, S., Yedla, P., Akunuri, R., Wlodkowic, D., Pabbaraja, S., Bhargava, S. K., Plebanski, M., & Kamal, A. (2026). (E)-4-(4-Acrylamidophenoxy)-N-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model. Molecules, 31(10), 1757. https://doi.org/10.3390/molecules31101757
Vancouver
Velma GR, Telukutla SR, Vankudoth J, Grewal AS, Privér S, Yedla P, et al. (E)-4-(4-Acrylamidophenoxy)-N-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model. Molecules. 2026;31(10):1757. doi:10.3390/molecules31101757
BibTeX
@article{Velma2026,
author = {Velma, Ganga Reddy and Telukutla, Srinivasa Reddy and Vankudoth, Jayaram and Grewal, Ajmer Singh and Privér, Steven and Yedla, Poornachandra and Akunuri, Ravikumar and Wlodkowic, Donald and Pabbaraja, Srihari and Bhargava, Suresh K and Plebanski, Magdalena and Kamal, Ahmed},
title = {(E)-4-(4-Acrylamidophenoxy)-N-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model},
journal = {Molecules},
year = {2026},
volume = {31},
number = {10},
pages = {1757},
doi = {10.3390/molecules31101757}
}
EUVIMED